Radiation for Lung Cancer: 264 Real Stories

264 stories match lung cancer and radiation. 187 of them mention chemotherapy.

Cancer Stories

Bill, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Bill's Patient Story

Patient Info: Bill, Male | Stage IV

Biomarkers: EGFR exon 21 mutation

Metastatic Site: Spine; brain; hips/bone

Stage IV EGFR exon 21 lung cancer improved in brain and spine on osimertinib, but later lung-mass growth led to clinical-trial treatment; Bill remained active in advocacy and felt positive about progress.

Lung Cancer Research Foundation
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

More than 5 years living with metastatic lung adenocarcinoma after stepwise molecular testing

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2 amplification, EGFR L858R mutation, PD-L1 <1%

Metastatic Site: brain, lung

As of April 2026, she remained on gefitinib with no active tumor lesions after complete regression of lung metastases, more than 5 years (66 months) after her original diagnosis.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Lung Squamous Cell CarcinomaLung Cancer

Stage IIIB lung cancer: heart inflammation from durvalumab immunotherapy, mistaken at first for tumor spreading to the heart

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: No actionable driver mutations identified; PD-L1 tumor proportion score <1%

She recovered cardiac function after treatment for durvalumab-associated myocarditis and remained without lung-cancer relapse or cardiac decline for more than 4 years, with no additional anticancer therapy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Long-term lung cancer control after immunotherapy-related diabetes

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 80%; EGFR, ALK, ROS1 and BRAF negative

Metastatic Site: brain|liver

After years of disease control off pembrolizumab, a new brain lesion appeared in December 2025 and was treated with focused radiation. He remained clinically stable under oncology follow-up.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

MET-Positive Lung Cancer Found After Eye Pain and Forehead Swelling

Patient Info: Anonymized, Male | Stage IV

Biomarkers: MET exon 14 skipping mutation

Metastatic Site: Right orbit; frontal skull/bone; left iliac bone

After 2 months of tepotinib, the primary lung lesion decreased from about 53 × 33 mm to 36 × 24 mm, metastatic sites were stable and the patient continued treatment without significant adverse events.

PubMed Central
OutcomeStable Disease / Ongoing Therapy
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung adenocarcinoma that spread to the thyroid 9 years later

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: thyroid

After the thyroid metastasis was removed, she started systemic chemotherapy and remained under oncology management.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

HER2-mutated lung cancer: restarting targeted therapy after lung inflammation

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: HER2 exon 20 insertion; PD-L1 negative

Metastatic Site: brain

Trastuzumab deruxtecan was restarted successfully after lung inflammation improved, but it was discontinued after 9 cycles when the cancer progressed.

PubMed Central
OutcomeSetback / Progression
Shannon, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR Lung Cancer: Shannon's Survivor Story

Patient Info: Shannon, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; TP53 mutation

Metastatic Site: cervical spine (C1/C2 and C4/C6), liver

As of June 2026, Shannon described no evidence of active disease: visible tumors were gone, the original lung mass had decreased from 10.8 cm to a 3.8 cm cavity, and targeted therapy continued to suppress possible remaining cells.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR-mutated lung adenocarcinoma: high-dose furmonertinib after CNS progression

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR L858R mutation. Later blood testing showed EGFR p.S553Y variation; CEA rose and fell with treatment.

Metastatic Site: brain/meninges; bilateral pleura/lungs; mediastinal…

As of June-September 2024, the left lung lesion was stable to slightly smaller on escalated furmonertinib, but brain/CNS lesions had progressed and required dose escalation to 240 mg/day; later imaging was declined.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Recurrent squamous lung cancer with tumor emboli, acute limb ischemia, brain metastases, and death

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: p40-positive; TTF-1-negative; PD-L1 not expressed / no PD-L1 reported in raw case

Metastatic Site: brain/cerebral metastases; tumor emboli in upper and…

The patient developed recurrent acute limb ischemia from tumor emboli, then new cerebral metastases, and died from advanced disease 7 months after the bilateral lower-limb ischemia presentation.

PubMed Central
OutcomeIn Memory
Montessa, who was diagnosed with Small Cell Lung CancerLung Cancer

Small Cell Lung Cancer: Montessa's Survivor Story

Patient Info: Montessa, Female, Under 40

As of June 2026, Montessa was sharing her recovery after limited-stage small cell lung cancer treatment with concurrent chemotherapy and radiation followed by brain radiation.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Heidi, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage III Non-Small Cell Lung Cancer: Heidi's Survivor Story

Patient Info: Heidi N., Female, 50s | Stage III

Biomarkers: No targetable mutation identified

As of June 2026, Heidi was featured as a lung cancer advocate after treatment for inoperable Stage IIIA NSCLC; scans through January 2021 had shown no evidence of disease.

The Patient Story
OutcomeCancer-Free / NED
Peter, who was diagnosed with Stage III Lung CancerLung Cancer

Stage III Lung Cancer: Peter's Survivor Story

Patient Info: Peter, Male, 70+ | Stage III

As of May 2026, Peter said his left-lung mass had gone after radiotherapy with chemotherapy and that he had returned to normal activities.

YouTube (AR search)
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV EGFR-mutated lung cancer responds after targeted therapy intolerance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; PIK3CA E545K mutation; acquired ROS1 rearrangement

Metastatic Site: pleura|pericardium|bone|lungs

Chemotherapy produced a partial response that remained sustained for 7 months at the latest follow-up.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutated Stage IV lung cancer with later brain progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR C797S mutation; acquired ROS1 rearrangement

Metastatic Site: brain|bone

She died about 20 months after diagnosis after brain progression and a severe postoperative stroke.

PubMed Central
OutcomeIn Memory
Jake, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Jake's Patient Story

Patient Info: Jake, Male, Under 40 | Stage IV

Biomarkers: ALK-positive mutation

Metastatic Site: brain; lung; ankle bone

As of May 2026, Jake was 28 and had lived more than 13 years with Stage IV ALK-positive lung cancer, with ongoing treatment history including targeted therapy, surgeries, radiation, clinical-trial therapy, and recent chemotherapy.

The Patient Story
OutcomeLiving With Cancer
Susie, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage III Non-Small Cell Lung Cancer: Susie's Survivor Story

Patient Info: Susie, Female | Stage III

As of May 2026, Susie described completed surgery, chemotherapy, and radiotherapy for Stage III non-small cell lung cancer and was advocating for smoke-free legislation; no NED status was stated.

Cancer Research UK
OutcomeSurvivorship / Completed Treatment